Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIR-2218 in chronic hepatitis B (Phase II, China)
CTR20201150Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Jun 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of elebsiran in Chronic Hepatitis B (CHB), sponsored by Brii Biosciences. Started Jun 2020; status: completed.
02
Drugs
elebsiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20201150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201150.